Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing.
Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS, PCAWG Structural Variation Working Group, Park PJ, PCAWG Consortium. · 2020
Read Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. by Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS, PCAWG Structural Variation Working Group, Park PJ, PCAWG Consortium. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7058534.txt.
Introduction
Cortés-Ciriano and co-authors map chromothripsis across human cancers in Nature Genetics. Chromothripsis is a catastrophic event in which a chromosome shatters and is stitched back in scrambled order, creating massive clustered rearrangements. Earlier work in selected cancers hinted it was more common than low-resolution data suggested. The team tested that idea across the Pan-Cancer Analysis of Whole Genomes collection.
They analysed 2,658 tumours from 38 cancer types. Chromothripsis proved pervasive, reaching a frequency above 50 percent in several cancer types. Classic events oscillate between two copy-number states, but many involved multiple chromosomes and extra structural changes. Repair signatures pointed to non-homologous end joining plus replication-based processes and templated insertions. The shattering can amplify oncogenes and disable genes, including mismatch-repair genes. The authors conclude chromothripsis is a major engine of genome evolution in cancer.
Catalog record
| CREATOR | Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS, PCAWG Structural Variation Working Group, Park PJ, PCAWG Consortium. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing By Isidro Cortés-Ciriano, Jake June-Koo Lee, Ruibin Xi, Dhawal Jain, Youngsook L Jung, Lixing Yang, Dmitry Gordenin, Leszek J Klimczak, Cheng-Zhong Zhang, David S Pellman, Peter J Park Published in: Nature Genetics DOI: 10.1038/s41588-019-0576-7 ABSTRACT Abstract Chromothripsis is a mutational phenomenon characterized by massive, clustered genomic rearrangements that occurs in cancer and other diseases. Recent studies in selected cancer types have suggested that chromothripsis may be more common than initially inferred from low-resolution copy-number data. Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), we analyze patterns of chromothripsis across 2,658 tumors from 38 cancer types using whole-genome sequencing data. We find that chromothripsis events are pervasive across cancers, with a frequency of more than 50% in several cancer types. Whereas canonical chromothripsis profiles display oscillations between two copy-number states, a considerable fraction of events involve multiple chromosomes and additional structural alterations. In addition to non-homologous end joining, we detect signatures of replication-associated processes and templated insertions. Chromothripsis contributes to oncogene amplification and to inactivation of genes such as mismatch-repair-related genes. These findings show that chromothripsis is a major process that drives genome evolution in human cancer. Subject terms: Cancer, Computational biology and bioinformatics, Genomics MAIN Chromothripsis is characterized by massive genomic rearrangements that are often generated in a single catastrophic event and localized to isolated chromosomal regions1–4. In contrast to the traditional view of tumorigenesis as the gradual process of the accumulation of mutations, chromothripsis provides a mechanism for the rapid accrual of hundreds of rearrangements in a few cell divisions. This phenomenon has been studied in primary tumors of diverse histological origins5–10, but similar random joining of chromosomal fragments has also been observed in the germline11. There has been considerable progress in elucidating the mechanisms by which chromothripsis may arise, including fragmentation and subsequent reassembly of a single chromatid in aberrant nuclear structures called micronuclei2,12 and the fragmentation of dicentric chromosomes during telomere crisis13,14. Chromothripsis is not specific to cancer as it can cause rare congenital human disease and can be transmitted through the germline11,15; it has also been described in plants, where it has been linked to micronucleation16. However, despite the recent rapid progress on elucidating the mechanisms of chromothripsis, much remains to be discovered regarding its cause, prevalence and consequences. A hallmark of chromothripsis is multiple oscillations between two or three copy-number (CN) states1,6. Applying this criterion to CN profiles inferred from SNP arrays, chromothripsis was initially estimated to occur in at least 2–3% of human cancers1. Subsequent studies of large array-based datasets gave similar frequencies: 1.5% (124 out of 8,227 tumors across 30 cancer types)17 and 5% (918 out of 18,394 tumors)18, with the highest frequencies detected for soft-tissue tumors (54% for liposarcomas, 24% for fibrosarcomas and 23% for sarcomas)18. These estimates relied on the detection of CN oscillations that are more-densely clustered than expected by chance8. Whole-genome sequencing (WGS) data provide a greatly enhanced view of structural variations (SVs) in the genome19, allowing us to generate a more nuanced set of criteria for chromothripsis and enhance detection specificity3. Our previous analysis of WGS data from cutaneous melanomas already found chromothripsis-like rearrangements in 38% of these tumors (45 out of 117)10; other studies using WGS data found 60–65% for pancreatic cancer5 and 32% for esophageal adenocarcinomas7. Whether these examples are outliers that reflect the unique biology of these tumors or whether they suggest a more general underestimation of the frequency of chromothripsis remained unclear. Motivated by the importance of chromothripsis during tumor evolution and the need for more-comprehensive analyses, we determined the frequency and spectrum of chromothripsis events in the WGS data for 2,658 patients with cancer comprising 38 cancer types generated by the ICGC and TCGA projects, and aggregated by the PCAWG Consortium. These sequencing data were re-analyzed with standardized pipelines to align to the human genome (reference build hs37d5) and to identify germline variants and somatic mutations20. In addition to deriving more-accurate estimates of the per-tumor type prevalence of chromothripsis, we determined the size and genomic distribution of such events, examined their role in the amplification of oncogenes or loss of tumor-suppressor genes, described their relationship to genome ploidy and investigated whether their presence is correlated with patient survival. Our chromothripsis calls can be browsed at the accompanying website (http://compbio.med.harvard.edu/chromothripsis/). RESULTS Prevalence of chromothripsis across cancer types We first sought to formulate a set of criteria for identifying chromothripsis events with varying complexities (Fig. 1a). The acknowledged model of chromothripsis posits that some of the DNA fragments generated by the shattering of the DNA are lost; thus, CN oscillations between two or three states1,6 are an obvious first criterion (Fig. 1a). Such deletions also lead to interspersed loss of heterozygosity (LOH) or altered haplotype ratios if there is only a single copy of the parental homolog of the fragmented chromatid. Although chromosome shattering and reassembly has been experimentally demonstrated to generate chromothripsis2, template-switching DNA-replication errors can generate a similar pattern21. Indeed, shattering and replication error models are not mutually exclusive and could co-occur2. Therefore, for the discussion below we will refer generally to ‘chromothripsis’ as encompassing both classes of models. [Figure: Overview of the chromothripsis-calling method and the frequency of events across 37 cancer types.a, Example of a region displaying the characteristic features of chromothripsis: cluster of interleaved SVs with equal proportions of SV types (that is, fragment joins), a CN profile that oscillates between two states and interspersed LOH. Details of the criteria are described in the Methods. Both the color scheme and the abbreviations shown in this figure are used throughout the manuscript. b, Classification of chromothripsis events. In a canonical event, more than 60% of the segments oscillate between two CN states; a tumor is classified as canonical if it showed at least one canonical chromothripsis event. c, Percentage of patients with chromothripsis events across the entire cohort. The fractions at the top of the bars are the number of tumors that showed high-confidence chromothripsis out of the total number of tumors of that type. The cancer type abbreviations used across the manuscript are as follows: Biliary-AdenoCA, biliary adenocarcinoma; Bladder-TCC, bladder transitional cell carcinoma; Bone-Benign, bone cartilaginous neoplasm, osteoblastoma and bone osteofibrous dysplasia; Bone-Epith, bone neoplasm, epithelioid; Bone-Osteosarc, sarcoma, bone; Breast-AdenoCA, breast adenocarcinoma; Breast-DCIS, breast ductal carcinoma in situ; Breast-LobularCA, breast lobular carcinoma; Cervix-AdenoCA, cervix adenocarcinoma; Cervix-SCC, cervix squamous cell carcinoma; CNS-GBM, central nervous system glioblastoma; CNS-Oligo, CNS oligodenroglioma; CNS-Medullo, CNS medulloblastoma; CNS-PiloAstro, CNS pilocytic astrocytoma; ColoRect-AdenoCA, colorectal adenocarcinoma; Eso-AdenoCA, esophagus adenocarcinoma; Head-SCC, head-and-neck squamous cell carcinoma; Kidney-ChRCC, kidney chromophobe renal cell carcinoma; Kidney-RCC, kidney renal cell carcinoma; Liver-HCC, liver hepatocellular carcinoma; Lung-AdenoCA, lung adenocarcinoma; Lung-SCC, lung squamous cell carcinoma; Lymph-CLL, lymphoid chronic lymphocytic leukemia; Lymph-BNHL, lymphoid mature B-cell lymphoma; Lymph-NOS, lymphoid not otherwise specified; Myeloid-AML, myeloid acute myeloid leukemia; Myeloid-MDS, myeloid myelodysplastic syndrome; Myeloid-MPN, myeloid myeloproliferative neoplasm; Ovary-AdenoCA, ovary adenocarcinoma; Panc-AdenoCA, pancreatic adenocarcinoma; Panc-Endocrine, pancreatic neuroendocrine tumor; Prost-AdenoCA, prostate adenocarcinoma; Skin-Melanoma, skin melanoma; SoftTissue-Leiomyo, leiomyosarcoma, soft tissue; SoftTissue-Liposarc, liposarcoma, soft tissue; Stomach-AdenoCA, stomach adenocarcinoma; Thy-AdenoCA, thyroid low-grade adenocarcinoma; and Uterus-AdenoCA, uterus adenocarcinoma.] To detect chromothripsis in WGS data, we developed ShatterSeek (Methods